Main content area

Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies

Kumar, Rajesh, Parray, Hilal Ahmed, Shrivastava, Tripti, Sinha, Subrata, Luthra, Kalpana
International journal of biological macromolecules 2019 v.135 pp. 907-918
antigens, autoimmune diseases, bacteriophages, biopharmaceuticals, clinical trials, humans, infectious diseases, medicine, monoclonal antibodies, neoplasms, recombinant antibodies, therapeutics
Monoclonal antibodies (mAbs) and their derivatives have achieved remarkable success as medicine, targeting both diagnostic and therapeutic applications associated with communicable and non-communicable diseases. In the last 3 to 4 decades, tremendous success has been manifested in the field of cancer therapy, autoimmune diseases, cardiovascular and infectious diseases. MAbs are the fastest growing class of biopharmaceuticals, with more than 25 derivatives are in clinical use and 7 of these have been isolated through phage display technology. Phage display technology has gained impetus in the field of medical and health sciences, as a large repertoire of diverse recombinant antibodies, targeting various antigens have been generated in a short span of time. A prominent number of phage display derived antibodies are already approved for therapy and significant numbers are currently in clinical trials. In this review we have discussed the various strategies employed for generation of monoclonal antibodies; their advantages, limitations and potential therapeutic applications. We also discuss the potential of phage display antibody libraries in isolation of monoclonal antibodies.